NCT02891980View on ClinicalTrials.gov

A Safety Trial to Test MVA-BN(R)-Filo and Ad26.ZEBOV Vaccines in Healthy Volunteers

PHASE1CompletedINTERVENTIONAL
Enrollment

65

Participants

Timeline

Start Date

March 24, 2017

Primary Completion Date

March 21, 2019

Study Completion Date

March 21, 2019

Conditions
Ebola DiseaseMarburg Disease
Interventions
BIOLOGICAL

Ad26 Zaire Ebola Vaccine

A recombinant adenovirus vector comprising a polynucleotide encoding a filovirus antigenic protein, wherein the recombinant adenovirus vector comprises an adenovirus 26 capsid protein.

BIOLOGICAL

MVA Multi-Filo Ebola Vaccine

A multivalent MVA-BN Filovirus vaccine, designed to protect against Ebola Zaire, Ebola Sudan and Marburg virus.

Trial Locations (1)

30322-1014

Emory University School of Medicine, Atlanta

All Listed Sponsors
lead

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

NCT02891980 - A Safety Trial to Test MVA-BN(R)-Filo and Ad26.ZEBOV Vaccines in Healthy Volunteers | Biotech Hunter | Biotech Hunter